Pharmacokinetics, Drug Metabolism, and Safety of Prasugrel and Clopidogrel

References

• . Anderson JL, Adams CD, Antman EM, . ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148–e304
   PubMed Web of Science ®Google Scholar
• . Ibanez B, Vilahur G, Badimon JJ. Pharmacology of thienopyridines: rationale for dual pathway inhibition. Eur Heart J Suppl. 2006;8( suppl G):G3–G9
   Web of Science ®Google Scholar
• . Farid NA, Smith RL, Gillespie TA, . The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35(7): 1096–1104
   PubMed Web of Science ®Google Scholar
• . Matsushima N, Jakubowski JA, Asai F, . Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets. 2006;17(4):218–226
   PubMed Web of Science ®Google Scholar
• . Brandt JT, Close SL, Iturria SJ, . Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–2436
   PubMed Web of Science ®Google Scholar
• . Mega JL, Close SL, Wiviott SD, . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362
   PubMed Web of Science ®Google Scholar
• . Gent M, Blakely JA, Easton JD, . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1(8649):1215–1220
   PubMed Web of Science ®Google Scholar
• . Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA. 1999;281(9):806–810
   PubMed Web of Science ®Google Scholar
• . King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, . 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117(2):261–295
   PubMed Web of Science ®Google Scholar
• . Smith SC Jr, Allen J, Blair SN, . AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363–2372
   PubMed Web of Science ®Google Scholar
• . Lau WC, Gurbel PA, Watkins PB, . Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109(2):166–171
   PubMed Web of Science ®Google Scholar
• . Gorchakova O, von Beckerath N, Gawaz M, . Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J. 2004;25(21):1898–1902
   Google Scholar
• . Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129(7): 1439–1446
   PubMed Web of Science ®Google Scholar
• . Sugidachi A, Asai F, Yoneda K, . Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol. 2001;132(1):47–54
   PubMed Web of Science ®Google Scholar
• . Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Norwalk, CT: Appleton and Lange; 1993
   Google Scholar
• . Greenblatt DJ, von Moltke L. Drug-drug interactions. In: Rodrigues AD, ed. Drugs and the Pharmaceutical Sciences. New York, NY: M. Dekker; 2002:xviii, 650
   Google Scholar
• . Chang GW, Kam PC. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia. 1999;54(1):42–50
   PubMed Web of Science ®Google Scholar
• . Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3): 311–320
   PubMed Web of Science ®Google Scholar
• . de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75–85
   PubMed Web of Science ®Google Scholar
• . Brockmoller J, Kirchheiner J, Schmider J, . The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72(4):438–452
   PubMed Web of Science ®Google Scholar
• . Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25( suppl 2):25–28
   PubMed Web of Science ®Google Scholar
• . Farid NA, Payne CD, Small DS, . Cytochrome P450 3 A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735–741
   PubMed Web of Science ®Google Scholar
• . Lau WC, Waskell LA, Watkins PB, . Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107(1):32–37
   PubMed Web of Science ®Google Scholar
• . Saw J, Steinhubl SR, Berger PB, ; Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003;108(8):921–924
   Google Scholar
• . Small DS, Farid NA, Li YG, . Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24(8):2251–2257
   PubMed Web of Science ®Google Scholar
• . Small DS, Farid NA, Payne CD, . Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4): 475–484
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Antman EM, Gibson CM, . Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152(4):627–635
   PubMed Web of Science ®Google Scholar
• . Gilard M, Arnaud B, Cornily JC, . Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–260
   PubMed Web of Science ®Google Scholar
• . Public Health Advisory: Updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). November 17, 2009
   Google Scholar
• . Preskorn S. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part 1). Psychopharmacology. 2003;9(2):150–158
   Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015
   PubMed Web of Science ®Google Scholar
• . Dumaual C, Miao X, Daly TM, . Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics. 2007;8(3):293–305
   PubMed Web of Science ®Google Scholar
• . Daly TM, Dumaual CM, Miao X, . Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin Chem. 2007;53(7):1222–1230
   Google Scholar
• . Wallentin L, Varenhorst C, James S, . Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirintreated patients with coronary artery disease. Eur Heart J. 2008;9(1):21–30
   Google Scholar
• . Korzonek M, Safranow K, Sulzyc-Bielicka V, Hajduk A. Gastroesophageal reflux disease among patients suffering from coronary artery disease [in Polish]. Ann Acad Med Stetin. 2008;54(2):41–46
   Google Scholar
• . Juul-Hansen P, Rydning A. On-demand requirements in patient with endoscopy-negative GERD: H2-blocker versus PPI. Aliment Pharmacol Ther. 2009;29(2):207–212
   Google Scholar
• . Liakakos T, Karamanolis G, Patapis P, Misiakos EP. Gastroesophageal reflux disease: medical or surgical treatment? Gastroenterol Res Pract. 2009;2009:371580
   PubMed Web of Science ®Google Scholar
• . Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12): 2616–2620
   PubMed Web of Science ®Google Scholar
• . Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126–142
   PubMed Web of Science ®Google Scholar
• . Hussar DA. Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride. J Am Pharm Assoc (2003). 2009;49(6):832–836
   Google Scholar
• . Plavix (clopidogrel bisulfate) film coated tablet [package insert]. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; Revised 2009
   Google Scholar
• . Farid NA, Payne CD, Ernest CS 2nd, . Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008;48(1):53–59
   Google Scholar
• . Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77(6):553–559
   PubMed Web of Science ®Google Scholar